Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATURN: Secukinumab and Neutrophils in PsA
NCT02854163Phase 2Completed
- Sponsor
- University of Liverpool
- Start
- Oct 2016
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of secukinumab in psoriatic arthritis (PsA) (2 arms), sponsored by University of Liverpool. Primary endpoints: Change from baseline in neutrophil apoptosis at 12 months and Change from baseline in neutrophil receptor expression at 12 months. Started Oct 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02854163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02854163.